SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Welcome to the GENT board. GENT has the first drug for VOD.
An SI Board Since July 2006
Posts SubjectMarks Bans Symbol
408 17 0 GENT
Emcee:  rareearth42 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
283VILLA GUARDIA (COMO), Italy, Aug. 1, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. ( GIRWIN JAMES FRANKEL-8/3/2013
282Must be interesting to be an analyst. Brean report sets a price target as 21. IRWIN JAMES FRANKEL17/26/2013
281New price targets: Brean 21 Wedbush 20IRWIN JAMES FRANKEL-7/26/2013
280Thanks rkrw! Do you think they'll run into any reimbursement obstacles for ghmm-7/26/2013
279I think it's basically irrelevant and hastened approval.rkrw-7/26/2013
278Thanks - I missed that. Probably was important to getting the approval.IRWIN JAMES FRANKEL-7/26/2013
277I found this interesting maybe on the quarterly call with Q&A they'll exghmm-7/26/2013
276from ghmm: Here are the links to the docs if you haven't seen them yet: IRWIN JAMES FRANKEL-7/26/2013
275Listened to the CC - there will be a replay. But there really was nothing of inIRWIN JAMES FRANKEL-7/26/2013
274Gentium Receives Positive Opinion From EMA's CHMP for Defitelio [graphic]PreIRWIN JAMES FRANKEL-7/26/2013
273Biotech/Pharma Catalysts for July 22-28, 2013 2013-07-22 10:41:26.622 GMT IRWIN JAMES FRANKEL-7/24/2013
272Hopefully they will have 2Q results out before the Wedbush presentation. IF tIRWIN JAMES FRANKEL-7/10/2013
271I wonder if anyone else has thought about the similarities this company has to Ughmm-7/9/2013
270Just noticed that there is a relatively recent presentation posted (June '13ghmm-7/8/2013
269>>As others have noted slide 15 points out a scientific advisory group mayIRWIN JAMES FRANKEL-6/4/2013
268Gentium Provides Update on Re-Examination of Defibrotide MAA to EMA [graphic]PreIRWIN JAMES FRANKEL-6/4/2013
267It would seem given the need Gentium should have qualified for conditional approghmm-6/4/2013
266Institutional holdings up 800K with Blackrock the biggest buyer in 1Q: Company IRWIN JAMES FRANKEL-5/16/2013
265>>We are pleased to report that Defibrotide usage increased by 32% [YOY] aIRWIN JAMES FRANKEL15/15/2013
264Gentium Reports First Quarter Financial Results [graphic]Press Release: Gentium IRWIN JAMES FRANKEL-5/14/2013
263Gentium to Request Re-Examination of CHMP Opinion on Defibrotide Tue April 16, IRWIN JAMES FRANKEL-4/16/2013
262Satellite Symposia on Defibrotide and Veno-Occlusive Disease at EBMT 39th AnnualIRWIN JAMES FRANKEL-4/10/2013
261Interesting there doesn't seem to be harmony on how best to proceed financeghmm-3/28/2013
260thanks for the notes Jim...a nice surprise (:>)fred hayes13/28/2013
259A few CC notes: - In 2012 about 1,100 pts treated in 40 countries and 85 institIRWIN JAMES FRANKEL23/28/2013
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News